Durgical
EN
Open the app

BAFF and APRIL: survival signals for B cells and plasma cells

  • Molecule

B cells and plasma cells die without a steady survival signal; too much signal keeps self-reactive B cells alive, too little leaves antibody deficiency.

Updated

What it is

BAFF (B-cell activating factor, also called BLyS) and APRIL are TNF-family cytokines made mainly by myeloid and stromal cells. Through three receptors, BAFF-R, TACI and BCMA, they keep naive B cells alive, support class switching and maintain long-lived plasma cells. High BAFF is found in lupus and Sjögren disease, TACI variants are common in common variable immunodeficiency, and BCMA is a major target in multiple myeloma.

Key facts

  • BAFF levels rise when B cells are depleted, which may help self-reactive B cells re-emerge after rituximab.
  • Transitional self-reactive B cells compete poorly for BAFF; excess BAFF lets them survive (a peripheral tolerance checkpoint).
  • APRIL produced in bone-marrow niches helps keep plasma cells alive for years.

Step by step

  1. Myeloid and stromal cells release BAFF; marrow niche cells supply APRIL.
  2. New transitional B cells compete for BAFF through BAFF-R; self-reactive ones, with weaker signals, lose and die.
  3. Survivors mature into naive B cells, still needing BAFF-R signals to stay alive.
  4. Activated and marginal-zone B cells use TACI for class switching and T-independent responses.
  5. Long-lived plasma cells use BCMA to receive APRIL in bone-marrow niches and survive for years.
  6. Excess BAFF rescues self-reactive B cells (autoimmunity); loss of BAFF-R or TACI function weakens antibody production.

Ligands and receptors

ReceptorLigandsMain cellsFunction and clinical link
BAFF-R (BR3)BAFF onlyTransitional and mature naive B cellsSurvival of the naive B-cell pool; BAFF-R deficiency → antibody deficiency
TACIBAFF and APRILActivated and marginal-zone B cellsT-independent responses and class switching; TNFRSF13B variants in some CVID patients
BCMAAPRIL (and BAFF)Plasma cellsSurvival of long-lived plasma cells in the marrow; target of CAR-T cells and bispecifics in myeloma

Clinical notes

  • Belimumab, an antibody against soluble BAFF, is approved for systemic lupus erythematosus and lupus nephritis.
  • Blockers of both BAFF and APRIL are being studied in IgA nephropathy and lupus.
  • Multiple myeloma: BCMA-directed CAR-T cells, bispecific antibodies and antibody–drug conjugates are in clinical use.
  • TACI variants are a risk factor for CVID but are also found in healthy people, so they are not diagnostic alone.

Common traps

  • BAFF and APRIL are made by T cells: they come mainly from myeloid and stromal cells, which is why B cells depend on their surroundings.
  • A TACI variant confirms CVID: TNFRSF13B variants raise risk but are also found in healthy people, so they are not diagnostic alone.
  • Rituximab depletes plasma cells and so removes all antibody: CD20 is absent on plasma cells, and BCMA-dependent long-lived ones persist.
  • BCMA is a B-cell marker found on naive B cells: BCMA is mainly on plasma cells, which makes it a target in multiple myeloma.

Test yourself

Think of the answer, then tap the question to see it.

Why does excess BAFF promote autoimmunity?

Self-reactive transitional B cells normally lose the competition for scarce BAFF and die; when BAFF is plentiful they survive and can make autoantibodies.

Why is BCMA a better target than CD20 in multiple myeloma?

Myeloma cells are plasma cells, which carry BCMA (their APRIL survival receptor) but usually lack CD20.

After rituximab, BAFF levels rise. Why might this matter for relapse?

With fewer B cells competing, more BAFF per cell is available, which may help self-reactive B cells survive as the pool regenerates.

Add to my cards (3)

Elsewhere in DurgiPedia

Connections

← All of immunology

Educational content on the immune system; not a treatment or individual vaccination guide and no substitute for a health professional's advice. No doses are given.

Sources: TNFRSF13B gene (MedlinePlus Genetics, US National Library of Medicine, 2024); Common variable immune deficiency (MedlinePlus Genetics, US National Library of Medicine, 2024); Autoimmune diseases (MedlinePlus, US National Library of Medicine, 2024).

Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake

Representative model, for educational purposes only.